BioLamina

Wade Predovic-Franey

🇮🇩 Indonesia

8.9

Reviewed: March 3, 2023

• - Regulatory Submission
• - 6 weeks February 2023
• - Biotech Startup

Our regulatory submission was handled with great care and expertise. The process was seamless, and their knowledge of the regulatory landscape was impressive. The team's support was invaluable, and I would not hesitate to use their services again.

Jessie Jakubowski

🇰🇷 South Korea

9.5

Reviewed: April 10, 2023

• - Gene Therapy Development
• - 12 weeks January - March 2023
• - Research Institution

The gene therapy project was managed exceptionally well, with innovative solutions provided at every stage. The team was highly collaborative and receptive to feedback, making it a truly joint effort. The results exceeded expectations.

Ms. Emma Mertz

🇮🇳 India

6.5

Reviewed: July 18, 2024

• - Regulatory Submission
• - 8 weeks May - July 2024
• - Pharmaceutical Company

The initial regulatory submission provided was incomplete, requiring additional work to meet the necessary standards. This resulted in unexpected costs and delays. The team corrected the issues, but it should have been right the first time.

Alex Toy

🇩🇪 Germany

8.8

Reviewed: July 5, 2023

• - Biostatistical Design
• - 4 weeks May - June 2023
• - Research Institution

The biostatistical support provided was top-notch, offering clear and actionable insights that were critical to the success of our study. The team was responsive and worked closely with us to ensure the analysis met our specific needs.

Sylvester Dooley III

🇸🇦 Saudi Arabia

6.3

Reviewed: November 7, 2024

• - Stability Studies
• - 16 months July 2023 - November 2024
• - Pharmaceutical Company

The stability studies conducted were lacking in detail, and we had to perform additional validation to ensure the results were reliable. This added extra time and cost to the project. The team was responsive to feedback, but the initial work was subpar.

Ruben Schmitt III

🇺🇸 United States

9.3

Reviewed: March 12, 2024

• - Market Access Strategy
• - 6 weeks January - February 2024
• - Pharmaceutical Company

The market access analysis provided strategic insights that were crucial to our launch strategy. The team's recommendations were data-driven and actionable, helping us to make informed decisions.

Walter Lowe

🇨🇳 China

8.9

Reviewed: July 3, 2024

• - Stability Studies
• - 18 months January 2023 - June 2024
• - Pharmaceutical Company

The stability studies were conducted with precision, and the reporting was clear and thorough. The results provided us with the necessary data to proceed with our regulatory submissions confidently.